Chart Illustrates Efforts by CMS to Commoditize Molecular Diagnostic Testing

The following chart helps to demonstrate how fees under the Palmetto Tier 1 and Tier 2 molecular fee schedules stack up against average fees under stacked coding for the higher volume tests.  The trend clearly shows a push to move the price point for most genetic testing services below $200 and commoditize diverse and high complexity molecular diagnostic services.

XiFin is tracking published MAC allowed amounts, see the list here